Higher reagent sales, due to resurgent testing demand, and the impact of yen depreciation pushed up net sales and profits
The year under review was characterized by major changes in the external environment, such as soaring raw material prices and logistics costs and rising geopolitical risks. However, these factors had little impact on performance. Year on year, net sales were up 19.2%, operating profit was up 34.8%, and profit attributable to owners of the parent was up 38.2%. At the exchange rates prevailing one year earlier, net sales would have been up 12.2% and operating profit up 16.4%.
In the diagnostics business, sales rose in all fields. We saw a major rise in reagent fields in our mainstay fields, centering on hematology*. In the immunochemistry field, we launched 18 reagent parameters in China, bringing the total to 37. We also entered a capital and business tie-up with KAINOS Laboratories Inc., through which we will seek to expand our global reagent lineup. In the medical robotics business, a total of 18 units have been installed. Sales in this business rose 67.1% year on year. In October 2021, we completed an application to expand regulatory approval in Japan for our robotic assisted surgery system to gynecology and gastroenterology. We aim to expand the system’s scope of use to surgery outside the field of urology.
We had initially forecast dividends for the year of ¥74 per share (interim and year-end dividends of ¥37 each). However, we raised that amount by ¥2 per share, to ¥76 (interim dividend of ¥37, year-end dividend of ¥39). This resulted in a consolidated dividend payout ratio of 36.0%. We plan to continue paying stable dividends going forward.
For the fiscal year ending March 31, 2023, we forecast consolidated net sales of ¥410.0 billion, operating profit of ¥76.0 billion and profit attributable to owners of the parent of ¥50.0 billion.* We anticipate annual dividends of ¥80 per share, up ¥4 year on year.
I would like to ask our shareholders for your continued support.